KeXing vaccine approved by Hong Kong government for emergency use.
In the midst of a controversy, the Hong Kong Secretary for Food and health announced Thursday the approval of the mainland-made Kexing Xinguan vaccine for emergency use in Hong Kong, effective immediately. The Hong Kong government held a press conference to explain the vaccination arrangements.
The first batch of vaccine is expected to arrive at 5 p.m. Friday, Kexing said in response to a Hong Kong media inquiry.
The outside world is concerned that Kexing did not publish the test data in medical journals, but still get recommended for use. Hong Kong Government expert adviser, Professor Xu Shuchang, Chair of Respiratory Medicine at CUHK, said the two scientific committees under the Centre for Health Protection will meet on Friday to review the data on the vaccine before making recommendations.
The expert committee convener Liu Zexing and member Xu Shucheng on Tuesday (16) had pointed out that field tests showed that the efficacy (efficacy) of Kexing’s vaccine ranged from about 50% to 91% in the group of people over 18 years old, and that the benefits outweighed the risks, and therefore recommended approval for use.
According to the report, the information submitted to the Hong Kong government by Kexing, the studies on Turkey and Indonesia are similar to those announced earlier, but the phase III clinical study in Brazil has more information, including data on more than 600 elderly people aged 60 or above, showing that the vaccine is about 50.6% effective in this group, similar to the younger group.
The Hong Kong Society of Hospital Pharmacists President Cui Junming pointed out in a radio interview on Wednesday that the efficiency of the Coxin vaccine is low, and that group immunization may require a vaccination rate of more than 80 percent.
Recent Comments